Clinical Trials Browser

binimetinib × Gastrointestinal × 90 days × Clear all

NCT04800822 2026-06-04

PF-07284892 in Participants With Advanced Solid Tumors

Phase 1 Terminated

CNSGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03693170 2026-05-29

ANCHOR-CRC

Phase 2 Completed

95 enrolled 30 charts

Gastrointestinal

Colorectal Neoplasms

NCT05615818 2026-05-19

SAFIR-ABC10

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT05554367 2026-05-13

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

Phase 2 Active not recruiting

GastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms

NCT05564403 2026-05-13

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Phase 2 Active not recruiting

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT02613650 2026-05-12

A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers

Phase 1 Completed

Gastrointestinal

Advanced KRAS Positive Metastatic Colorectal Cancer

NCT04132505 2026-04-06

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms